SAN FRANCISCO, December 7, 2017 /PRNewswire/ --
The global angina pectoris drugs market is
expected to be valued at USD 10.6
Billion by 2022, as per a new report by Grand View Research,
Inc. The global angina pectoris market is collectively driven by
demand for disease-modifying and targeted treatments, increased
expenditure on healthcare and availability of effective treatment
methods across the emerging markets.
(Logo:
http://photos.prnewswire.com/prnh/20160524/371361LOGO )
Additionally, the rising prevalence and incidence of angina
pectoris is anticipated to fuel the market growth. Chronic stable
angina pectoris has a prevalence of 2.0-4.0% in developed markets
such as the U.S., the U.K., Germany, France, Italy, Spain
and Japan. The prevalence of
angina pectoris rises sharply with age in both genders, ranging
from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men aged 65-74,
and from 0.1-1.0% in women aged 45-54 to 10.0-15.0% in women aged
65-74. The disease symptoms can be managed by following a healthy
lifestyle.
Browse full research report with TOC on "Angina
Pectoris Drugs Market Analysis, By Therapeutic Class (Beta
Blockers, Calcium Antagonists, Nitrates, Anticoagulants, ACE
inhibitors, Ranolazine), By Major
Markets, And Segment Forecasts, 2016 - 2022"
at:
https://www.grandviewresearch.com/industry-analysis/angina-pectoris-market
Further Key Findings From the Report Suggest:
- The U.S. dominated this space by accounting for more than 33.0%
of the market share in 2016 due to increasing incidence of cardiac
disorders and presence of key manufacturers in the U.S.
- The angina pectoris drug market is commercially meaningful,
however branded sales are in decline as generics dominate a larger
portion of prescriptions. Though the market is fragmented, key
players such as Sanofi, Gilead, AstraZeneca and Pfizer hold
significant market positions
- Biosimilar development is emerging as a promising market
opportunity in angina pectoris therapeutics. Multiple biosimilars
have gained approvals in the U.S., European and Indian markets
- China offers strong
opportunity for market expansion due to removal of price caps on
all medicine categories, the ongoing Healthy China 2020 healthcare
reform and supportive 12th Five-Year Plan measure, which targets
biotechnology as the key development sector
- Changing regulatory scenario in the U.S. presents favorable
environment for disruptive technologies in healthcare. In the EU,
the new Clinical Trials Regulation (EU No. 536/2014) will impact
clinical trials of Advanced Therapy Medicinal Products. Industry
concerns regarding ROIs on novel therapies remains a challenge to
drug development.
- Some of the key players operating in this industry are Sanofi,
Gilead, AstraZeneca, Pfizer, Eli Lilly, Amgen and
GlaxoSmithKline
Browse related reports by Grand View Research:
- Inhalable Drugs Market -
https://www.grandviewresearch.com/industry-analysis/inhalable-drugs-market
- Antiseptics And Disinfectants Market -
https://www.grandviewresearch.com/industry-analysis/antiseptics-and-disinfectants-market
- Cancer Therapeutics And Biotherapeutics Market
-https://www.grandviewresearch.com/industry-analysis/cancer-therapeutics-biotherapeutics-market
- Anti-Inflammatory Peptides Market -
https://www.grandviewresearch.com/industry-analysis/anti-inflammatory-peptides-market
Grand View Research has segmented the global angina pectoris
drugs market based on therapeutic class:
- Therapeutic Class Outlook (% market share; 2016 -
2022)
- Beta Blockers
- Calcium Antagonists
- Anticoagulants
- Anti-Platelets
- Others
- Nitrates
- Anti-anginal (Ranolazine)
- ACE inhibitors
- Regional Outlook (% market share; 2016 - 2022)
- U.S.
- U.K.
- France
- Germany
- Italy
- Spain
- Japan
Read Our Blog By Grand View Research:
https://www.grandviewresearch.com/blogs/healthcare
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company
provides syndicated research reports, customized research reports,
and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant
and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: http://www.grandviewresearch.com